The two-question test
Whether a peptide COA is research-only or injectable-grade comes down to two questions:
- Was the material tested for bacterial endotoxin (USP <85>)?
- Was the material tested for viable microbial contamination (USP <71> sterility)?
If yes to both, the COA supports injectable use. If no to either, the COA is research-only — the material may still be high-purity and accurately identified, but it has not been characterized for the failure modes that cause injection-site reactions or systemic adverse events.
What research-only actually covers
A typical research-only peptide COA includes:
- HPLC purity % — main peak area vs related impurities. Tells you how clean the peptide is.
- LC-MS identity — molecular ion observed vs theoretical m/z. Tells you the right molecule is in the vial.
- Net Peptide Content (NPC) — active mass vs gross salt mass. Tells you how much actual active per vial.
- TFA / acetate residual — counter-ion quantification. Tells you the salt form composition.
That is sufficient information to characterize what's in the vial chemically. It is not sufficient to know whether it's safe to inject.
What injectable-grade adds
An injectable-grade COA adds two safety assays:
- USP <85> bacterial endotoxin (LAL) — quantifies lipopolysaccharide from Gram-negative bacterial cell walls. Endotoxin causes pyrogenic response (fever, chills, septic-shock-like reaction at higher doses) when injected, even at very low concentrations. Sterile manufacturing alone is not sufficient because endotoxin persists even after the bacteria that produced it are killed by sterilization.
- USP <71> sterility (14-day culture) — detects viable bacterial or fungal contamination via 14-day incubation in two separate growth media. This is the gold-standard test for "is this material actually sterile."
Both are time-consuming and consume sample. The 14-day sterility incubation is the binding constraint on Full Disclosure panel turnaround. Endotoxin and sterility together can't be done on the same vial because both are destructive.
Why the price gap exists
The price difference between our Identity + Potency panel ($499) and Full Disclosure panel ($899) reflects:
- Two extra vials of sample required (sterility + endotoxin are destructive).
- LAL Endosafe kit cost — proprietary recombinant-factor-C or LAL reagent cartridges run $30-60 per test.
- 14-day incubation — instrument and lab space committed for the duration of the sterility test.
- Heavy metals (ICP-MS) — included in Full Disclosure for the full-injectable-COA standard.
- Analyst review — additional QA review for injectable-grade attestation, which carries higher liability.
When research-only is actually fine
Research-only COAs are appropriate for:
- In-vitro research — cell-culture assays, biochemical characterization, structural studies.
- Method-development work — calibration standards, reference materials for analytical method validation.
- QC checks on purchase orders — verifying supplier claims of purity and identity before formulation.
- Stability monitoring — time-course studies of purity drift in lyophilized vs reconstituted material.
When research-only is NOT enough
If the material is going to be injected — whether by a clinician dosing compounded GLP-1, a research subject in an investigational protocol, or anyone in any context — research-only is not enough. The endotoxin and sterility data don't exist, which means the material has not been characterized for the failure modes that matter for injection safety.
We see this gap exploited in two patterns:
- Research-grade material sold "for research use only" but in formats clearly intended for injection — sterile-filled 10mL vials, bacteriostatic water companion products, syringe kits. The legal disclaimer doesn't change the analytical gap.
- Compounded peptide products with abbreviated COAs — some compounding pharmacies issue COAs covering purity and identity but skip USP <85> / <71>, relying on cleanroom manufacturing as a substitute. Cleanroom controls reduce risk but don't replace direct testing.
What a credible injectable-grade COA actually looks like
An injectable-grade COA from a properly-equipped lab should include all of:
- HPLC purity %, with related-impurity peaks identified.
- LC-MS identity confirmation with mass-accuracy in ppm.
- Net Peptide Content (UV-corrected, water- and counter-ion- adjusted).
- TFA / acetate residual by ion chromatography.
- USP <85> endotoxin in EU/mg with PPC spike recovery and lambda correlation.
- USP <71> sterility, 14-day result, both growth media (fluid thioglycolate + soybean-casein digest).
- ICP-MS heavy metals against USP <232> PDE limits.
- Analyst signature, accession number, instrument identifiers, calibration timestamps.
A COA missing any of those is fine for research; it is not enough for injection.
Summary
Research-only and injectable-grade peptide COAs differ on two assays: USP <85> endotoxin and USP <71> sterility. Without both, the analytical record is incomplete for injection use. With both, the record covers the failure modes that matter. The price gap reflects real cost (additional sample, kit reagents, 14-day incubation) — not margin.
See the Full Disclosure panel on every peptide compound page: Semaglutide, Tirzepatide, Retatrutide, BPC-157, TB-500, PT-141.
